Table 3.
Neuroimaging for Alzheimer’s disease and mild cognitive impairment outpatients by race and clinic
| Neuroimaging | Total patients | African American | Non-Hispanic white | p* |
| Enterprise-wide outpatients | ||||
| AD/MCI patients | 3,072 | 651 | 2,421 | |
| Amyloid PET | 40 (1.2%) | 3 (0.5%) | 37 (1.5%) | 0.023 |
| FDG-PET | 94 (2.8%) | 14 (2.2%) | 80 (3.3%) | 0.15 |
| Brain MRI | 979 (28.7%) | 211 (32.4%) | 768 (31.7%) | 0.74 |
| Memory Disorders | ||||
| AD/MCI patients | 1,047 | 151 | 896 | |
| Amyloid PET | 40 (3.3%) | 3 (2.0%) | 37 (4.1%) | 0.26 |
| FDG-PET | 71 (5.8%) | 7 (4.6%) | 64 (7.1%) | 0.30 |
| Brain MRI | 376 (30.8%) | 69 (45.7%) | 307 (34.2%) | 0.0078 |
| Other Neurology | ||||
| AD/MCI patients | 783 | 112 | 671 | |
| Amyloid PET | 0 (0%) | 0 (0%) | 0 (0%) | - |
| FDG-PET | 19 (2.2%) | 2 (1.8%) | 17 (2.5%) | 0.69 |
| Brain MRI | 338 (38.8%) | 62 (55.4%) | 276 (41.1%) | 0.0054 |
| Primary Medicine | ||||
| AD/MCI patients | 311 | 149 | 162 | |
| Amyloid PET | 0 (0%) | 0 (0%) | 0 (0%) | - |
| FDG-PET | 4 (1.2%) | 1 (0.7%) | 3 (1.9%) | 0.41 |
| Brain MRI | 71 (22.0%) | 42 (28.2%) | 29 (17.9%) | 0.042 |
| Geriatrics | ||||
| AD/MCI patients | 616 | 196 | 420 | |
| Amyloid PET | 0 (0%) | 0 (0%) | 0 (0%) | - |
| FDG-PET | 1 (0.2%) | 0 (0%) | 1 (0.2%) | - |
| Brain MRI | 58 (9.1%) | 21 (10.7%) | 37 (8.8%) | 0.46 |
*p values are from conditional maximum likelihood or median unbiased exact tests comparing the proportions of African American AD/MCI patients receiving each type of neuroimaging to the proportion of non-Hispanic white patients receiving the same imaging, within each clinical setting. Data presented as counts (percentages of the AD/MCI patients). AD, Alzheimer’s disease; MCI, mild cognitive impairment; PET, positron emission tomography; FDG, fluorodeoxyglucose; MRI, magnetic resonance imaging.